Detection of HER2 Status in Breast Cancer: Comparison of Current Methods with MLPA and Real-time RT-PCR

Pazhoomand, Reza; Keyhani, Elahe; Banan, Mehdi; Najmabadi, Hossein; Khodadadi, Faranak; Iraniparast, Alireza; Feiz, Farnaz; Majidzadeh, Keivan; Bahman, Ideh; Moghadam, Fatemeh Aghakhani; A, Sobhani; Muhammadnejad, Ahad; Abedini, Seyedeh Sedigheh; Behjati, Farkhondeh

doi:10.7314/apjcp.2013.14.12.7621

Cited by 16 publications

(14 citation statements)

References 41 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The HER2 gene is involved in intracellular signaling transduction pathways leading to cell growth and differentiation (Di Fiore et al, 1987;Kauraniemi et al, 2006;Unal et al, 2013). Studies have suggested that abnormal expression of HER2 gene by mutation or amplification may play an important role in tumor genesis (Auersperg et al, 2001;Garcia-Velasco et al, 2008;Cuadros and Villegras, 2009;Moatter et al, 2011;Duman et al, 2012;Pazhoomand et al, 2013;Unal et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

“…HER2 has been reported to be overexpressed or amplified in a variety of human tumors (Nicholson et al, 2001;Rubin and Yarden, 2001;McAlpine et al, 2009;Ghaffari et al, 2011;Wang et al, 2011;Sardari et al, 2012;Duman et al, 2012;Panagiotou et al, 2012; RESEARCH ARTICLE Pazhoomand et al, 2013;Unal et al, 2013;Ziaian et al, 2014). The clinical significance of HER2 status in many tumor types is not yet clear except for breast, gastric, or gastroesophageal junction cancer patients (Nicholson et al, 2001;Gravalos and Jimeno, 2008;García-Velasco et al, 2008;Moatter et al, 2011;Wang et al, 2011;Duman et al, 2012;Pazhoomand et al, 2013;Tai et al, 2013;Unal et al, 2013).…”

Section: Introductionmentioning

confidence: 99%

“…The clinical significance of HER2 status in many tumor types is not yet clear except for breast, gastric, or gastroesophageal junction cancer patients (Nicholson et al, 2001;Gravalos and Jimeno, 2008;García-Velasco et al, 2008;Moatter et al, 2011;Wang et al, 2011;Duman et al, 2012;Pazhoomand et al, 2013;Tai et al, 2013;Unal et al, 2013). Amplification and overexpression of HER2 have been identified in breast cancer (Slamon et al, 1987;Slamon et al, 1989;Wolff et al, 2007;Ghaffari et al, 2011;Moatter et al, 2011;Pazhoomand et al, 2013;Tai et al, 2013;Unal et al, 2013) and are associated with a poor prognosis (Wilson et al, 2002;Erdogan et al, 2003;Nathanson et al, 2003).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

HER2 Expression in Ovarian Mucinous Carcinomas in Tunisia

Missaoui

Abdelkarim²,

Ayachi³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

Background: Ovarian mucinous carcinoma has a poor prognosis in advanced stages and a poor response to conventional chemotherapy. An efficient treatment is not yet available. We heere investigated HER2 expression and the potential for trastuzumab therapy in ovarian mucinous tumors. Materials and Methods: Immunohistochemistry was performed in formalin-fixed, paraffin-embedded tissue from 27 ovarian mucinous tumors including 14 carcinomas and 13 borderline tumors diagnosed in the Pathology Department, Farhet Hached Hospital, Sousse, between 1993 and 2013. The HercepTest (DAKO) was used for immunohistochemistry. Results: HER2 expression was observed in only one borderline tumor (7.7%) and in 14.3% of mucinous carcinomas of the ovary. Conclusions: Our results suggest that trastuzumab therapy would be an option for patients with mucinous carcinoma when the tumor has HER2 overexpression.

show abstract

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

HER2 Expression in Ovarian Mucinous Carcinomas in Tunisia

Missaoui

Abdelkarim²,

Ayachi³

et al. 2014

Asian Pacific Journal of Cancer Prevention

View full text Add to dashboard Cite

show abstract

“…Some researchers have previously studied the probability of HER‐2 2+ IHC breast cancers for HER‐2 amplification . In a study which was also in Iranian population 36% of HER‐2 2+ samples were HER‐2 amplified . Another study with a relatively large population of 1735 breast cancer HER‐2 amplification were seen in 14% of patients .…”

Section: Discussionmentioning

confidence: 90%

Validity of immunohistochemistry method in predicting HER‐2 gene status and association of clinicopathological variables with it in invasive breast cancer patients

Gheybi

Baradaran

Mohajeri³

et al. 2016

APMIS

View full text Add to dashboard Cite

Human epidermal growth factor receptor-2 is an important and prognostic factors and one of the most targeted proteins in breast cancer's therapy. There is no globally accepted method for determining its status. Here, we aimed to evaluate the immunohistochemistry method validity in predicting HER-2 status by Fluorescence in situ hybridization method and investigate some clinicopathological variables association with HER-2 amplification. A total of 190 HER-2 2+ and 3+ by immunohistochemistry (IHC) invasive breast cancer cases were enrolled in this study. Fluorescence in situ hybridization (FISH) was performed for these cases using FDA criteria and the association between clinicopathological variables and HER-2 status evaluated. Study consisted of 190 invasive breast cancer patients (160 HER-2 2+ and 30 HER-2 3+). HER-2 FISH amplification according to FDA criteria was found 27.5% (44/160 patients) in HER-2 2+ patients and 83.3% (25/30 patients) in HER-2 3+ patients. Tumors with HER-2 amplification were more likely to be ER-negative (51.0% vs 31.2%, p = 0.013) and PR-negative (52.9% vs 27.0%, p < 0.001). This study showed that immunohistochemistry is not a good method for evaluating HER-2 status and decision-making about trastuzumab therapy even with 3+ score patients. However, this result may not be too strong for IHC 3+ cases due to the limited number of these patients in this study.

show abstract

“…A recent report suggested that MLPA could rule out Her-2 amplification in 75% of ISH-evaluated Her-2-equivocal carcinomas [14]. Her-2 mRNA expression analysis by quantitative reverse transcription-PCR (qRT-PCR) may also be of help to determine the status of Her-2 [21]. Her-2 D-FISH equivocal cases determined by the ASCO/CAP 2013 guidelines always have an increase in CEP17 copy number and hence a <2.0 Her-2/CEP17 ratio.…”

Section: Discussionmentioning

confidence: 99%

Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines

Qian

Wen

Yang

et al. 2016

Breast Cancer Res Treat

View full text Add to dashboard Cite

Dual-probe fluorescence in situ hybridization (D-FISH) is a widely accepted method to determine the gene amplification status of human epidermal growth factor receptor 2 (Her-2). In 2013, the American Society of Clinical Oncology/College of American Pathologists (ASCO/CAP) updated the guidelines on the Her-2 testing for invasive breast cancer (BCa). The interpretation criteria for D-FISH changed accordingly. In this study, we compared the Her-2 FISH statuses based on the 2013 and 2007 ASCO/CAP guidelines in 1931 cases of BCa with Her-2 D-FISH testing at our hospital. We analyzed the clinicopathologic features of cases with equivocal results by the 2013 ASCO/CAP guidelines. Although the guideline update significantly improved the detection rate of Her-2 amplification, it also significantly increased the rate of equivocal results, posing a dilemma for clinical management. The equivocal results had good reproducibility. The distribution of D-FISH equivocal cases did not correlate with Her-2 status by immunohistochemistry, suggesting that Her-2 D-FISH equivocality may not reflect Her-2 overexpression. Compared with Her-2 negative cases by D-FISH, Her-2 D-FISH equivocal cases had higher Ki-67 expression, higher histological grade, more frequent lymph node metastasis, and lower estrogen receptor α expression, indicating a group of BCa with worse prognosis. The clinical significance of Her-2 equivocal results by D-FISH warrants further investigation.

show abstract

Detection of HER2 Status in Breast Cancer: Comparison of Current Methods with MLPA and Real-time RT-PCR

Cited by 16 publications

References 41 publications

HER2 Expression in Ovarian Mucinous Carcinomas in Tunisia

HER2 Expression in Ovarian Mucinous Carcinomas in Tunisia

Validity of immunohistochemistry method in predicting HER‐2 gene status and association of clinicopathological variables with it in invasive breast cancer patients

Assessment of dual-probe Her-2 fluorescent in situ hybridization in breast cancer by the 2013 ASCO/CAP guidelines produces more equivocal results than that by the 2007 ASCO/CAP guidelines

Contact Info

Product

Resources

About